Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,055
NCT01667341
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jul 31, 2012
Completion: May 9, 2014
NCT01995617
Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine
Phase: Phase 1
Start: Nov 30, 2013
Completion: Feb 28, 2015
NCT02114060
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
Phase: Phase 2
Start: Jul 31, 2014
Completion: Feb 29, 2016
NCT02116998
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
Start: Sep 30, 2014
Completion: Apr 30, 2016
NCT02300142
Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study
Start: Jan 31, 2015
Completion: Jun 30, 2016
NCT02515175
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
Start: Nov 30, 2015
Completion: May 25, 2017
NCT02910284
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
Phase: N/A
Start: Sep 16, 2016
Completion: Jul 14, 2017
NCT03146403
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
Start: May 24, 2017
Completion: Jun 11, 2018
NCT03633110
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Start: Aug 29, 2018
Completion: Feb 28, 2022
NCT04596033
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Start: Nov 11, 2020
Completion: Jun 27, 2022